- Home
- INM vs SNN Comparison
INM vs SNN Comparison
Compare INM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SNN
- Stock Information
- Founded
- INM 1981
- SNN 1856
- Country
- INM Canada
- SNN United Kingdom
- Employees
- INM N/A
- SNN N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- INM Health Care
- SNN Health Care
- Exchange
- INM Nasdaq
- SNN Nasdaq
- Market Cap
- INM 3.2M
- SNN 12.6B
- IPO Year
- INM N/A
- SNN 1999
- Fundamental
- Price
- INM $3.05
- SNN $30.17
- Analyst Decision
- INM
- SNN Hold
- Analyst Count
- INM 0
- SNN 3
- Target Price
- INM N/A
- SNN $27.50
- AVG Volume (30 Days)
- INM 5.8M
- SNN 913.6K
- Earning Date
- INM 05-12-2025
- SNN 07-31-2025
- Dividend Yield
- INM N/A
- SNN 2.39%
- EPS Growth
- INM N/A
- SNN 56.15
- EPS
- INM N/A
- SNN 0.47
- Revenue
- INM $4,920,990.00
- SNN $5,810,000,000.00
- Revenue This Year
- INM N/A
- SNN $6.87
- Revenue Next Year
- INM N/A
- SNN $5.19
- P/E Ratio
- INM N/A
- SNN $31.95
- Revenue Growth
- INM N/A
- SNN 4.70
- 52 Week Low
- INM $1.72
- SNN $23.69
- 52 Week High
- INM $15.70
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- INM 51.64
- SNN 58.76
- Support Level
- INM $3.32
- SNN $28.40
- Resistance Level
- INM $5.50
- SNN $30.77
- Average True Range (ATR)
- INM 0.37
- SNN 0.42
- MACD
- INM 0.04
- SNN 0.06
- Stochastic Oscillator
- INM 24.38
- SNN 74.47
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.